Han Zhang1, Jaehoon Cho1, James Buxbaum2. 1. Department of Medicine, Division of Gastroenterology, Keck School of Medicine, University of Southern California, D & T Building Room B4H100, 1983 Marengo St, Los Angeles, CA, 90033-1370, USA. 2. Department of Medicine, Division of Gastroenterology, Keck School of Medicine, University of Southern California, D & T Building Room B4H100, 1983 Marengo St, Los Angeles, CA, 90033-1370, USA. jbuxbaum@usc.edu.
Abstract
PURPOSE OF REVIEW: Endoscopic retrograde cholangiopancreatography (ERCP) is a commonly performed procedure to manage pancreaticobiliary disease. Post-ERCP pancreatitis (PEP) is the most common adverse event of ERCP with a significant burden of morbidity and cost. RECENT FINDINGS: Appropriate indication and counseling is mandatory especially for patients at increased risk for PEP such as those with suspected sphincter of Oddi dysfunction, pancreatic indications, and a prior history of PEP. Guidewire-facilitated deep cannulation is favored over contrast injection. High-quality trials support the use of rectal administered non-steroidal anti-inflammatory agents and pancreatic duct stent placement for high-risk patients. There is emerging evidence favoring the use of rectal NSAIDs and aggressive hydration in average-risk patients though further studies are required. There is also growing interest in the use of combination therapies as well such as pancreatic stents in combination with NSAIDs. The initial step towards PEP prevention involves careful patient selection and informed decision-making. Endoscopists should use several approaches to mitigate the risk of PEP, including guidewire-assisted cannulation, pancreatic stent placement, and rectal NSAIDs use for high-risk patients. The exact role of aggressive hydration and combination therapies needs to be further investigated.
PURPOSE OF REVIEW: Endoscopic retrograde cholangiopancreatography (ERCP) is a commonly performed procedure to manage pancreaticobiliary disease. Post-ERCP pancreatitis (PEP) is the most common adverse event of ERCP with a significant burden of morbidity and cost. RECENT FINDINGS: Appropriate indication and counseling is mandatory especially for patients at increased risk for PEP such as those with suspected sphincter of Oddi dysfunction, pancreatic indications, and a prior history of PEP. Guidewire-facilitated deep cannulation is favored over contrast injection. High-quality trials support the use of rectal administered non-steroidal anti-inflammatory agents and pancreatic duct stent placement for high-risk patients. There is emerging evidence favoring the use of rectal NSAIDs and aggressive hydration in average-risk patients though further studies are required. There is also growing interest in the use of combination therapies as well such as pancreatic stents in combination with NSAIDs. The initial step towards PEP prevention involves careful patient selection and informed decision-making. Endoscopists should use several approaches to mitigate the risk of PEP, including guidewire-assisted cannulation, pancreatic stent placement, and rectal NSAIDs use for high-risk patients. The exact role of aggressive hydration and combination therapies needs to be further investigated.
Authors: James A Disario; Martin L Freeman; David J Bjorkman; Padraic Macmathuna; Bret T Petersen; Philip E Jaffe; Thomas G Morales; Lee J Hixson; Stuart Sherman; Glen A Lehman; M Mazen Jamal; Firas H Al-Kawas; Mukul Khandelwal; Joseph P Moore; Gregory A Derfus; Priya A Jamidar; Francisco C Ramirez; Michael E Ryan; Karen L Woods; David L Carr-Locke; Stephen C Alder Journal: Gastroenterology Date: 2004-11 Impact factor: 22.682
Authors: Xavier J N M Smeets; David W da Costa; Paul Fockens; Chris J J Mulder; Robin Timmer; Wietske Kievit; Marieke Zegers; Marco J Bruno; Marc G H Besselink; Frank P Vleggaar; Rene W M van der Hulst; Alexander C Poen; Gerbrand D N Heine; Niels G Venneman; Jeroen J Kolkman; Lubbertus C Baak; Tessa E H Römkens; Sven M van Dijk; Nora D L Hallensleben; Wim van de Vrie; Tom C J Seerden; Adriaan C I T L Tan; Annet M C J Voorburg; Jan-Werner Poley; Ben J Witteman; Abha Bhalla; Muhammed Hadithi; Willem J Thijs; Matthijs P Schwartz; Jan Maarten Vrolijk; Robert C Verdonk; Foke van Delft; Yolande Keulemans; Harry van Goor; Joost P H Drenth; Erwin J M van Geenen Journal: Trials Date: 2018-04-02 Impact factor: 2.279
Authors: Savio George Barreto; Aida Habtezion; Anna Gukovskaya; Aurelia Lugea; Christie Jeon; Dhiraj Yadav; Peter Hegyi; Viktória Venglovecz; Robert Sutton; Stephen J Pandol Journal: Gut Date: 2020-09-24 Impact factor: 23.059